Building upon this risk stratification, recent studies in adult patients with CBF-AML have demonstrated that maintenance therapy with HMA (decitabine) significantly improves outcomes in patients with persistent molecular MRD (39, 40). Here, CEBPZ is linked to acute myeloid leukemia.